X

Pfizer Ltd Stock Analysis

Large Cap
Evaluated by 2537 users | BSE: 500680 | NSE: PFIZER |
Pharmaceuticals & Drugs

Pfizer is a Public Limited Company, incorporated under the Indian Companies Act, 1913, having its registered office in Mumbai, Maharashtra and is listed on the BSE Limited and the National Stock Exchange of India Limited

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Pfizer Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation
Value Creation Index Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 21.37%15.06%14.25%18.76%11.3%14.17%10.6%13.94%14.4%15.49%
Value Creation Index 1.270.500.420.870.130.410.060.390.44NA
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 9391,0931,0491,1121,8532,0121,9661,9692,0822,152
Y-o-Y Gr. Rt.-16.4%-4.1%6%66.7%8.6%-2.3%0.1%5.7%3.4%
Adjusted EPS (Rs.) 57.561.7971.2273.7132.2963.9252.8677.6789.41106.83
Y-o-Y Gr. Rt.-7.5%15.3%3.5%-56.2%98%-17.3%46.9%15.1%19.5%
Book Value per Share (Rs.) 292.41437.21567.81220.64431.28472.92528.72586.49658.22742.18
Adjusted Net Profit 172184213220148292242355409489
Net Op. Cash Flow (Rs. Cr.) 60.124.5-1613211334532933297.8323
Debt to Cash Flow from Ops 00000.020.010.010.010.030.01
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Pfizer Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 9.7%3%3.1%3.4%
Adjusted EPS 7.1%27%26.4%19.5%
Book Value per Share 10.911.51212.8
Share Price 17.4% 24.4% 30.1% 15.8%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 21.2114.9414.1718.711.2314.1410.5513.9314.3715.26
Operating Profit Margin (%) 21.531817.5621.620.5521.6217.8125.4527.2926.88
Net Profit Margin (%) 18.2716.8720.2619.787.9714.5312.318.0519.6522.71
Debt to Equity 0000000000
Working Capital Days 294207185169143160154165185199
Cash Conversion Cycle 1639332120-1-10-40-27-4
Corporate Governance What do we look at?
Corporate Governance
Board Credentials
Promoter's holding
Transparency
Integrity
Entity Percentage Holding
Promoters 63.92%
Institutions 16.52%
Non-Institutions 19.55%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

MoneyWorks4Me analysed the past 10-year performance of Pfizer Ltd and arrived at the following conclusion:

Past 10 year's financial track record indicates that Pfizer Ltd is a good quality company. However, for specific investment actions please connect with your investment advisor.

The 5-year analysis of Pfizer Ltd's performance infers:

Pfizer Ltd earnings have grown by 27%, whereas share price has appreciated 24.4% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Pfizer Ltd share prices over the last 10 years. Here is what we found out:

Pfizer Ltd share price has appreciated 15.2% annually over the past ten years.

Pfizer is a Public Limited Company, incorporated under the Indian Companies Act, 1913, having its registered office in Mumbai, Maharashtra and is listed on the BSE Limited and the National Stock Exchange of India Limited

Pfizer scientists have produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial

Pfizer is a Public Limited Company, incorporated under the Indian Companies Act, 1913, having its registered office in Mumbai, Maharashtra and is listed on the BSE Limited and the National Stock Exchange of India Limited

Pfizer scientists have produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections. The company is taking on some of the world's most difficult diseases, including cancer, arthritis, and osteoporosis.

Business area of the company

Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.

Awards

2001

  • OPPI Brand Excellence Award for Minipress XL.

2002

  • Express Pharma Biz Award for overall performance.
  • Rated as one of India's most socially responsive companies. Awarded by FICCI-Socio Economic Development Foundation for our Social Responsiveness.

2003

  • Voted as the 5 'Most Respected Company' in the Pharma sector (Business World).
  • Corporate Advertising Campaign won a Silver Award at the ABBY-All India Awards for Creative Excellence. Gelusil brand received a Silver Award for printing advertising.
  • Golden Peacock National Training Special Commendation for Training practices.

2004

  • Ranked 5 among all pharmaceutical companies, with respect to corporate image, field-force, and promotional programs (AC Nielsen-ORG Marg 'Corporate Image Survey').
  • Ranked 1 among all Pharma MNCs & 4 among all Pharma Companies by Business World.
  • Kewal Handa, CFO Pfizer Limited receives the ‘India CFO 2004 - Excellence in Finance in an MNC’ by International Market - Assessment Group.

2005

  • Golden Peacock Innovative Service Award for Prime MD Today (Daxid).
  • PC Quest 'Best IT Implementation Users Choice' award for OPTILEARN.
  • Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera.
  • Ranked 1 among multinationals and #3 among all pharmaceuticals, in the Business World survey.

2006

  • Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera.
  • Ranked 1 among multinationals and 3 among all pharmaceuticals, in the Business World survey.
  • Kewal Handa, Managing Director Pfizer, awarded the Bharat Shiromani award for his outstanding contribution in the pharmaceutical industry.

2007

  • Reader’s Digest Trusted Brand Asia - Gold Award 2007’ in the vitamin and health supplement category for Becosules.

2008

  • Frost & Sullivan Brand Strategy Leadership Award for Becosules in the Indian Dietary Supplement Market.
  • Pfizer India was recently conferred the ‘Innovative Training Practices’ Award for promoting effective and optimum utilization of human resource through education and training by the Indian Society for Training and Development (ISTD).

2009

  • Pfizer Limited (India) conferred the Multinational Pharmaceutical Company of the Year by Frost & Sullivan.

2010

  • Pfizer Limited awarded the Most Admired Pharmaceutical Company of the Year by Pharma Leaders Magazine.
  • Kewal Handa, Country Manager - Pfizer Limited recognized as Pharma Professional of the Year by Pharma Leaders Magazine.
  • Pfizer wins the Community Engagement Award at the Asia Responsible Entrepreneurship Awards 2010 in India.

2011

  • Pfizer India has been recognized as one of The Best Companies to Work For by Business Today magazine.

2012

  • J.D. Power and Associates has honored the MS LifeLines call center with certification for an outstanding customer service experience. This is the first time J.D. Power has recognized a pharmaceutical call center. Click Here.

2013

  • GBCHealth Business Leadership Award - in recognition for the Global Health Fellows program. This award is given annually to a company or business leader with a deep and long-term commitment to global health that extends beyond the business objective of the company itself. Caroline Roan will be accepting the award on behalf of Pfizer.
  • Business Action on Health Award in Application of Core Competence for Global Health Fellows Program (commendation). Oonagh Puglisi will be accepting the award for the GHF program.
  • Business Action on Health Award in Partnership/Collective Action for Advancing Cancer & Tobacco Control in China Program. Danlong Feng, Corporate Affairs Director, Pfe China, will be accepting the award.
  • QUESTAR Award - The International Awards Festival for Excellence in Video Communications Pfizer was awarded the Grand -- best of category -- in Annual Reports in the 2013 Questar Awards.
  • Telly Award - For over a quarter century, the Telly statuette has been a symbol of creative excellence. Pfizer was awarded - Bronze at the 2013 Telly's for online videos.

Milestones:

  • 1849: Charles Pfizer & Company established. 1' product for treatment of intestinal worms is a success.
  • 1880: Pfizer manufactures Citric Acid. Rapid growth on the back of aerated drinks demand.
  • 1882: Alexander Fleming discovers penicillin.
  • 1944: Pfizer finds a way to mass-produce Penicillin.
  • 1950: Terramycin, the 1st pharmaceutical sold in the US under the Pfizer label.
  • 1950: India operation launched, with HQ in Mumbai.
  • 1966: Pfizer listed on the Bombay Stock Exchange.
  • 1989: Dolonex (Feldene) launched in India.
  • 1993: Amlogard (Norvasc) launched in India.
  • 1996: Launch of MinipressXL, an anti hypertensive drug.
  • 1998: Launch of Viagra, for erectile dysfunction.
  • 1999: Pfizer listed on the National Stock Exchange.
  • 2000: Launch of Magna& a unique hospital antibiotic.
  • 2002: Futuristic tablet manufacturing Goa plant commissioned in a record 13 months.
  • 2003 Completes merger with Parke-Davis (India) Ltd.
  • 2005: Announces merger with Pharmacia Healthcare ltd.
  • 2006: Launch of LYRICA (pregaballn for treatment of neuropathic pain)
  • 2008: Launch of Champix - a non-nicotine smoking cessation prescription drug.
  • 2010: Launch of Prevenar 13, vaccine for prevention of pneumococcal disease and included later in India’s Universal Immunization Programe.
  • 2015: Completed merger with Wyeth Limited.
  • 2016: Launched Xeljanz-the first oral Janus Kinase (JAK) inhibitor.
  • 2017: Acquires 2 breakthrough brands- Meronem, Neksium.
  • 2019: Reorganizes into 3 distinct business units: Pfizer Biopharma Group, UpJohn and Consumer Healthcare. New purpose and values unveiled.
  • 2019: Launches novel anti-bacterial Zavicefta in India.
  • 2020: Launch of Zinforo, a noval cephalosporin indicated for treatment of adult patients with community- acquired Pneumonia.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback